COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

1. Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?Children (Basel, Switzerland) · 2023
   Article
2. Typical and Atypical Clinical Presentation of COVID-19 Infection in Children in The Top of Pandemic in EL-Minia Governorate (Two Center Experience).Mediterranean journal of hematology and infectious diseases · 2022
   Article
3. Pediatric Atypical Hemolytic Uremic Syndrome Advances.Cells · 2021
   Review
4. The Spectrum of Manifestations of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) Infection in Children: What We Can Learn From Multisystem Inflammatory Syndrome in Children (MIS-C).Frontiers in medicine · 2021
   Review

Corrections and comments

• Comment on
  Eculizumab treatment for renal failure in a pediatric patient with COVID-19.2020

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as